What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

December 8, 2025Blood

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

View Full Paper

Ask AI

Bookmark

Authors

OLOla Landgren APAbhishek Pandey JHJames E. Hoffman

Discussion

Member takes

Overview

Clinical trial shows 100% overall response with daratumumab and teclistamab in high-risk smoldering multiple myeloma, indicating a new treatment avenue.

Key Points

The combination therapy achieved notable rates of minimal residual disease negativity at 12 cycles of treatment with no patients progressing to active multiple myeloma.
Following this clinical trial, all evaluable patients demonstrated 10-5 MRD-negativity, with 85% achieving the desired outcomes according to international standards.
Patients receiving treatment experienced manageable adverse events, including neutropenia, yet no serious complications such as cytokine release syndrome occurred.
These findings underscore the potential of the teclistamab and daratumumab combination in achieving sustained minimal residual disease negativity and improving progression-free survival.

Cite This Study

Landgren et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e174 https://doi.org/10.1182/blood-2025-5775

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

View Full Paper

Ask AI

Bookmark

Authors

OLOla Landgren APAbhishek Pandey JHJames E. Hoffman

Discussion

Member takes

Overview

Clinical trial shows 100% overall response with daratumumab and teclistamab in high-risk smoldering multiple myeloma, indicating a new treatment avenue.

Key Points

The combination therapy achieved notable rates of minimal residual disease negativity at 12 cycles of treatment with no patients progressing to active multiple myeloma.
Following this clinical trial, all evaluable patients demonstrated 10-5 MRD-negativity, with 85% achieving the desired outcomes according to international standards.
Patients receiving treatment experienced manageable adverse events, including neutropenia, yet no serious complications such as cytokine release syndrome occurred.
These findings underscore the potential of the teclistamab and daratumumab combination in achieving sustained minimal residual disease negativity and improving progression-free survival.

Cite This Study

Landgren et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e174 https://doi.org/10.1182/blood-2025-5775

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark